AI-generated · cited to primary sources · not investment advice · How we research
Alkem Lab
Our verdict on Alkem Lab isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
U.S. sales grew by 28% Y-o-Y in Q2 FY26, far outperforming the mid-single-digit guidance, leading management to upgrade expectations to double-digit growth for the full year. (1 exceeded across 1 tracked commitment)
“So overall, I think our guidance was about mid-single-digit kind of growth from U.S. markets. I will maintain at least that growth.”
US sales grew by 28.0% YoY in Q2 FY26, far exceeding the mid-single-digit guidance, driven by new launches like Sacubitril/Valsartan and CDMO business. (1 exceeded across 1 tracked commitment)
“So, our expected launch is around September or October, somewhere around that time.”
See the full cited Management analysis of Alkem Lab
How durable is the business?
Alkem is successfully outperforming the market in chronic and sub-chronic therapy areas like Anti-Diabetics and Neuro/CNS, strengthening its brand moat. (1 expanding)
“our chronic business as far as branded generic business is concerned. We are close to 22% of our business is from chronic and which is if you see our last 3- or 4-years trend, every year, we are improving it internally by at least 1%.”
Alkem continues to outperform the market in chronic and sub-chronic segments like Anti-Diabetics (1.4x market growth) and Neuro/CNS (1.2x market growth). (5 expanding)
“We have outperformed the IPM across seven key therapies, namely GI... Anti-Diabetics at 1.4x, Neuro/CNS at 1.2x and Respiratory, 1.4x of the market.”
See the full cited Business Model analysis of Alkem Lab
Where does growth come from?
Alkem is aggressively entering the high-growth anti-diabetic space with new launches like Semaglutide and Tirzepatide, growing this segment 2x faster than the market when excluding these new molecules. (1 new trend, 2 accelerating across 3 signals)
“a key highlight has been the successful day 1 launch of semaglutide in the month of March 2026... we could garner a market -- unit market share of around 11% and we expect it to go up even further in the coming months.”
While total international sales saw a full-year decline, the 'Other International' (Non-US) segment is accelerating sharply, growing 28.2% in the final quarter compared to 8.7% for the full year. (5 accelerating across 5 signals)
“International sales were INR4,610 million with a Y-o-Y growth of 22.5%.”
See the full cited Future Growth analysis of Alkem Lab
What could break the thesis?
The company is subject to government price controls in India, which limits its ability to raise prices to offset rising costs. [REGULATORY]
“What pricing risk we do to mitigate, I think nobody in the world can do that because the pricing is going by regulations which we have to follow.”
The risk is easing as the company reported a positive impact of 0.8% to 0.9% on gross margins due to lower API prices. (1 easing, 2 intensifying, 1 high-severity)
“the current geopolitical environment and evolving global supply chain dynamics have resulted in increased logistics costs along with some pressure on APIs and the packaging materials.”
See the full cited Risk analysis of Alkem Lab
Read the full thesis on Alkem Lab
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.